參考文獻
[1] Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456(7221):470-476.
[2] Alec Paschalis, Adam Sharp, Jonathan C. Welti, et al. Alternative splicing in prostate cancer. Nature Reviews Clinical Oncology. 15, 663–675 (2018)
[3] Lu Z, Huang Q, Park JW, Shen S, Lin L,et al. Transcriptome-wide landscape of pre-mRNA alternative splicing associated with metastatic colonization. Mol Cancer Res 2015, 13:305-318.
[4] Trincado JL, Sebesty en E, Pag es A, Eyras E. The prognostic potential of alternative transcript isoforms across human tumors. Genome Med 2016, 8:85.
[5] Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 30 splice site selection through use of a different branch point. Cell Rep 2015, 13:1033-1045.
[6] Alsafadi S, Houy A, Battistella A, Popova T, Wassef M, et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun 2016, 7:10615.
[7] Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 2015, 27:617-630.
[8] Bechara EG, Sebestyen E, Bernardis I, Eyras E, Valcarcel J. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol Cell 2013, 52:720-733.
[9] Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell 2005, 20:881-890.
[10] Ghigna C, De Toledo M, Bonomi S, Valacca C, Gallo S, et al. Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives. RNA Biol 2010, 7:495-503.
[11] Buljan M, Chalancon G, Eustermann S, Wagner GP, Fuxreiter M, et al. Tissue-specific splicing of disordered segments that embed binding motifs rewires protein interaction networks. Mol Cell 2012, 46:871-883.
[12] Ellis JD, Barrios-Rodiles M, Colak R, Irimia M, Kim T, et al. Tissue-specific alternative splicing remodels protein-protein interaction networks. Mol Cell 2012, 46:884-92.
[13] Goldstein LD, Lee J, Gnad F, Klijn C, Schaub A, et al. Recurrent loss of NFE2L2 exon 2 is a mechanism for Nrf2 pathway activation in human cancers. Cell Rep 2016, 16(10):2605-2617.
[14] Green RE, Lewis BP, Hillman RT, Blanchette M, Lareau LF, et al. Widespread predicted nonsense-mediated mRNA decay of alternatively-spliced transcripts of human normal and disease genes. Bioinformatics 2003, 19 (Suppl 1):i118-121.
[15] Sebestyen E, Singh B, Minana B, Pages A, Mateo F, et al. Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. Genome Res 2016, 26:732-744.
[16] Feinberg AP, Koldobskiy MA, Gondor A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet 2016, 17:284-29.
[17] Anczukow O. Krainer AR. Splicing-factor alterations in cancers. RNA 2016, 22:1285-1301.
[18] Das S, Anczukow O, Akerman M, Krainer AR. Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC, Cell Rep 2012; 1:110-117.
[19] David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvat kinase mRNA splicing in cancer. Nature 2010, 463:364-368.
[20] Dvinge H, Kim E, Abdel-Wahab O, Bradley RK. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer 2016, 16:413-430.
[21] Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 30 splice site selection through use of a different branch point. Cell Rep 2015, 13:1033-1045.
[22] Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov 2013, 3:1122-1129.
[23] Brooks AN, Choi PS, de Waal L, Sharifnia T, Imielinski M, et al. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One 2014, 9:e87361.
[24] Supek F, Minana B, Valcarcel J, Gabaldon T, Lehner B. Synonymous mutations frequently act as driver mutations in human cancers. Cell 2014, 156:1324-1335.
[25] Sterne-Weiler T, Sanford JR. Exon identity crisis: diseasecausing mutations that disrupt the splicing code. Genome Biol 2014, 15:201.
[26] Salton M, Kasprzak WK, Voss T, Shapiro BA, Poulikakos PI MT. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Nat Commun Dis 2015, 6:7103.
[27] Naftelberg S, Schor IE, Ast G, Kornblihtt AR. Regulation of alternative splicing through coupling with transcription and chromatin structure. Annu Rev Biochem 2015, 84:165-198.
[28] Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T. Epigenetics in alternative pre-mRNA splicing. Cell 2011, 144:16-26.
[29] Grosso AR, Leite AP, Carvalho S, Matos MR, Martins FB, et al. Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma. Elife 2015, 4:e09214.
[30] Simon JM, Hacker KE, Singh D, Brannon AR, Parker JS, Weiser M, Ho TH, Kuan PF, Jonasch E, Furey TS et al. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res 2014, 24:241-250.
[31] Shkreta L, Chabot B. The RNA splicing response to DNA damage. Biomolecules 2015, 5:2935-2977.
[32] Shkreta L, Toutant J, Durand M, Manley JL, Chabot B. SRSF10 connects DNA damage to the alternative splicing of transcripts encoding apoptosis, cell-cycle control, and DNA repair factors. Cell Rep 2016, 17:1990-2003.
[33] Savage KI, Gorski JJ, Barros EM, Irwin GW, Manti L,et al. Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability. Mol Cell 2014, 54:445-459.
[34] Sebestyen E, Zawisza M, Eyras E. Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer. Nucleic Acids Res 2015, 43:1345-1356.
[35] Shen S, Wang Y, Wang C, Wu YN, Xing Y. SURVIV for survival analysis of mRNA isoform variation. Nat Commun 2016, 7:11548.
[36] Lee SC-W, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med 2016, 22:976-986.
[37] Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
[38] Salton M, Kasprzak WK, Voss T, Shapiro BA, Poulikakos PI MT. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing. Nat Commun Dis 2015.
[39] Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 2015; 5:1282-1295.
[40] Havens MA, Hastings ML. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016, 44 6549-6563.
[41] Salton M, Misteli T. Small molecule modulators of premRNA splicing in cancer therapy. Trends Mol Med 2016, 22:28-37.
[42] Hsu TY-T, Simon LM, Neill NJ, Marcotte R, Sayad A, et al. The spliceosome is a therapeutic vulnerability in MYCdriven cancer. Nature 2015, 525:384-388.
[43] Koh CM, BezziM, Low DH, Ang WX, Teo SX, et al. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature 2015, 523:96-100.
[44] Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009, 25(9): 1105-1111.
[45] Foissac S, Sammeth M. ASTALAVISTA: dynamic and flexible analysis of alternative splicing events in custom gene datasets. Nucleic Acids Res 2007, 35(Web Server issue):W297-9.
[46] Katz Y, Wang ET, Airoldi EM, Burge CB. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat Methods 2010, 7(12):1009-15.
[47] Trapnell C, Williams BA, Pertea G, Mortazavi AM, Kwan G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nature Biotechnology 2010, 28(5):511-515.
[48] Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc 2016, 11(9):1650-1667.
[49] Sharon D, Tilgner H, Grubert F, Snyder M. A single-molecule long-read survey of the human transcriptome. Nat Biotechnol 2013, 31(11):1009-14.
[50] Minoche AE, Dohm JC, Schneider J, Holtgräwe D, Viehöver P, et al. Exploiting single-molecule transcript sequencing for eukaryotic gene prediction. Genome Biol 2015, 16:184.
備註：部分文字編譯自網絡文章